Puma Biotechnology (NYSE:PBYI) is inching closer to its transformation from a research and development (or R&D) biopharmaceutical company to a full-fledged commercial organization. This company which has in-licensed development and commercialization rights for oral and intravenous formulations of irreversible tyrosine kinase inhibitor or TKI, neratinib, and also another irreversible TKI, PB357, achieved the first major milestone for 2017 on May 24, 2017. On this day, FDA's Oncologic Drugs Advisory Committee or ODAC recommended approval for Nerlynx (neratinib) as extended adjuvant therapy for patients suffering with early stage, human epidermal growth factor receptor type 2 - positive or HER2-positive breast cancer after being previously treated with surgery and adjuvant treatment with Roche Holdings' (OTCQX:RHHBY) Herceptin (trastuzumab).
Besides this indication, Puma Biotechnology expects neratinib to demonstrate efficacy in other cancers such a non small cell lung cancer and tumors related to expression or over-mutation in HER2 such as HER2-positive cancer, HER-2 cancer that has metastasized to brain, HER2-positive neoadjuvant breast cancer.
Hence, there is high probability that Neratinib can prove to be a blockbuster drug for Puma Biotechnology. I believe this is a solid reason for considering the company as a favorable investment opportunity in 2017. In this article, I will explain the key drivers that make Puma Biotechnology a compelling investment opportunity in 2017.
Extended adjuvant setting is a larger underserved market segment
Currently, the target breast cancer market in extended adjuvant setting comprises around 36,000 patients in USA and 34,000 in EU. In 2015, Herceptin's sales in adjuvant indication were around $4.5 billion to $5.0 billion. All these patients form a target market for neratinib in the following year. Currently, letrozole is the only FDA approved therapy in extended adjuvant setting.
Puma Biotechnology expects to launch Neratinib as extended adjuvant breast cancer therapy in 2017
In July 2016, Puma Biotechnology filed new drug application or NDA with FDA, seeking approval for neratinib in extended adjuvant setting for early stage HER2-overexpressed/amplified breast cancer. The regulatory agency accepted the application in September 2016.
Further, the European Medicines Agency or EMA also validated Puma's application for neratinib in extended adjuvant setting in August 2016. On advice of EMA, in March 2017, the company revised its label to only include those early stage HER2+ breast cancer patients who had been previously treated for up to 1 year with adjuvant herceptin. Puma Biotechnology initiated a managed access program for neratinib in this indication in Q4 2016 and an expanded access program in Q1 2017.
While all these have been major milestones for the company in the past, the upcoming milestone will be FDA approval for orally administered neratinib in extended adjuvant setting, anticipated in 3Q 2017.
This approval is expected to be mainly based on results obtained from phase 3 trial, ExteNET, in which neratinib managed to hit its primary endpoints. In the intent-to-treat or ITT population, the 2-year disease free survival or DFS in neratinib arm was seen to be 93.9% while that in the placebo arm was 91.6%, which implies absolute improvement of 2.4%. In ITT population, there has been a 2.5% absolute improvement in 5-year DFS for neratinib arm as compared to placebo arm.
In case of patients confirmed with HER+ breast cancer, neratinib demonstrated 2-year DFS of 94.7%, while it was only 90.6% for the placebo arm. While this is an absolute improvement of 4.1%, the 5-year DFS with neratinib in HER+ patients is slightly higher at 4.4%.
Data from ExteNET trial has also shown 33% reduction in risk of disease recurrence for patients in neratinib arm as compared to those in placebo arm in ITT population. Further, for confirmed HER+ early stage breast cancer patients, the reduction in risk of disease recurrence for those on neratinib therapy in extended adjuvant setting is as high as 49%.
All these statistics are in line with those seen for the already approved extended adjuvant breast cancer drug, letrozole, as well as data obtained from development trials for hormone receptor positive or HR+ adjuvant breast cancer therapies, Pfizer's (NYSE:PFE) Aromasin and AstraZeneca's (NYSE:AZN) Arimidex. This implies that there are high chances for neratinib to secure FDA approval in extended adjuvant setting.
Neratinib has demonstrated higher benefit as adjuvant therapy in HR+ breast cancer patients
For HR+ breast cancer patients in ExteNET trial, the adjuvant therapy of neratinib demonstrated DFS rate of 95.4%, while the placebo arm showed DFS of 91.2%. This implied an absolute benefit of 4.2% after 2 years.
For 5-year period, the DFS with neratinib in HR+ patients was 91.7% while that in placebo arm was 86.9%, implying 4.8% absolute benefit.
Neratinib has demonstrated superior results in HR+ patients mainly on account of dual suppression of the crosstalk between estrogen receptor-positive or ER+ and HER+. Since ER+ breast cancer patients in the ExteNET trial were already on background endocrine therapy, it helped suppress the ER while neratinib suppressed both EGFR and HER2. This dual suppression has been seen only in neratinib and not in trials of other breast cancer drugs such Roche Holdings Herceptin and Novartis' (NYSE:NVS) Tykerb.
In case of HR- patients, however, ExteNET trial demonstrated improvement with neratinib between months 0 to 12 as compared to placebo. This was essentially when the patients were being administered the drug. However, the benefit in DFS in the neratinib arm over placebo arm seemed to become statistically insignificant over 5 year horizon.
Puma Biotechnology has also introduced loperamide prophylaxis therapy to prevent diarrhea resulting from neratinib.
Prior to Puma Biotechnology in-licensing Neratinib, it was being tested on 3,000 patients in various trials. It was seen that these patients suffered from grade 3 or grade 4 diarrhea in the first 28 days after initiating therapy. However, this could be treated with antidiarrheal drug, loperamide.
Puma Biotechnology is instead focusing on preventing this side-effect of neratinib using loperamide prophylaxis. Data from multiple studies has shown that the rate of grade 3 diarrhea reduced from the range of 30% to 53% in case of no loperamide prophylaxis to the range of 0% to 17% with loperamide prophylaxis. The total duration of diarrhea also dropped from 14 days to 2 days with loperamide prophylaxis.
Since ExteNET trial did not involve any anti-diarrheal prophylaxis therapy, Puma Biotechnology separately studied the impact of loperamide prophylaxis alone and in combination with other anti-inflammatory agents in extended adjuvant setting in early stage HER2+ breast cancer patients in another phase 2 trial, CONTROL. Data from this trial showed that while rate of grade 3 diarrhea in ExteNET trial was 39.8%, loperamide prophylaxis reduced the rate to 30.7%, loperamide and budesonide prophylaxis to 23.4%, and loperamide and colestipol to 11.5%.
Further, while the duration of diarrhea in ExteNET trial was 59 days, the various prophylaxis regimens in the CONTROL trial have brought the down to the range of 8 to 12 days. Episodes of diarrhea were also brought down from 8 in ExteNET trial to the range of 2 to 4 in CONTROL trial.
The CONTROL trial has also shown improvement in tolerability for the drug, which was being mainly affected due to diarrhea.
All this shows that the major side-effect of Neratinib, diarrhea, is easily manageable with effective prophylaxis therapy. Further, it is only seen that grade 3 diarrhea was witnessed by patients only in first cycle or first 28 days of neratinib therapy.
The company's cash reserves can sustain its operations through mid-2018
At the end of Q1 2017, Puma Biotechnology had $194 million worth cash reserves on its balance sheet. The company's cash burn rate in Q1 2017 was $36.0 million. This can be considered representative for all the quarters in 2017, as Puma has been highly involved in preparing for regulatory approval and commercial launch of neratinib. Based on these assumptions, the company can sustain its business operations upto the first half of 2018, without depending on external funding.
Further, with a solid oncology drug in the pipeline, Puma Biotechnology will also not find it difficult to raise capital from the public, either as equity or debt. Hence, the company seems to be at a comfortable position.
Investors should not ignore certain company-specific risks
Today, Puma Biotechnology is equivalent to neratinib. In absence of any commercial product or advanced stage research product, Puma Biotechnology is excessively dependent on the successful commercial launch of Neratinib. Since the product has not yet received FDA approval for even a single indication, this may prove to be too risky investment for investors with average risk appetite.
Further, the company also does not have proven marketing and distribution capabilities. In absence of a strong commercial partner, Puma Biotechnology may land up being commercially unsuccessful, despite securing FDA approval for neratinib.
Investors should consider these major risk factors while considering Puma Biotechnology as an opportunity in 2017.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
See original here:
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity - Seeking Alpha
- Plant biotechnology 3 - Video - January 1st, 2014 [January 1st, 2014]
- Press Release - April 9th, 2014 [April 9th, 2014]
- Biotech Suffers Record Exit at Largest ETF Signaling Turn - April 9th, 2014 [April 9th, 2014]
- Biotechnology World Congress 2014 | Biotechnology ... - April 9th, 2014 [April 9th, 2014]
- What is Biotechnology? - Access Excellence @ the National ... - April 9th, 2014 [April 9th, 2014]
- What is Biotechnology? - BIO | Healing, Fueling and ... - April 9th, 2014 [April 9th, 2014]
- Biotechnology - Wikipedia, the free encyclopedia - April 9th, 2014 [April 9th, 2014]
- IUBP Day5 2 Emerging Opportunities in Biotechnology - Video - April 9th, 2014 [April 9th, 2014]
- B.Tech(Biotechnology), BATCH 2008/09, SVPUAT MEERUT.............. FRIENDS FOREVER...... - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Japan Pharma - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 India Pharma - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Rising Stars - Video - April 10th, 2014 [April 10th, 2014]
- Nasdaq Rout Curbs 2000-Like Boom in Israeli Share Sales - April 15th, 2014 [April 15th, 2014]
- A Glimpse into Biotechnology - Video - April 15th, 2014 [April 15th, 2014]
- Biotechnology: gel electrophoresis, PCR - Video - April 15th, 2014 [April 15th, 2014]
- Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade - Video - April 16th, 2014 [April 16th, 2014]
- Biotechnology Program - University of California, Davis - April 17th, 2014 [April 17th, 2014]
- Biotechnology in Action (Arizona) - Video - April 17th, 2014 [April 17th, 2014]
- France protests new EU approved genetically modified corn ScienceDaily - Video - April 17th, 2014 [April 17th, 2014]
- Drug manufacture and Biotechnology '14 - SCOPS - final phase ( Auditing ) - Video - April 19th, 2014 [April 19th, 2014]
- Mucosis Partners With Chinese Firm Changchun BCHT Biotechnology - April 22nd, 2014 [April 22nd, 2014]
- Biotechnology-2014: Meeting the Needs of a Changing World - April 22nd, 2014 [April 22nd, 2014]
- New patenting guidelines are needed for biotechnology - April 22nd, 2014 [April 22nd, 2014]
- Biotechnology is so cool - Video - April 22nd, 2014 [April 22nd, 2014]
- Bharat Book Presents : Biotechnology Equipment Markets in China - Video - April 22nd, 2014 [April 22nd, 2014]
- New patenting guidelines needed for biotechnology, experts argue - April 24th, 2014 [April 24th, 2014]
- biotechnology videos - Video - April 24th, 2014 [April 24th, 2014]
- Kristi Snell, VP Research and Biotechnology for Metabolix, Inc. - Video - April 24th, 2014 [April 24th, 2014]
- 4th Annual International Conference: Advances in Biotechnology 2014 - Video - April 24th, 2014 [April 24th, 2014]
- Edmonds School District Biotechnology - Video - April 25th, 2014 [April 25th, 2014]
- World congress on Biotechnology - Video - April 25th, 2014 [April 25th, 2014]
- Bahir Dar university biotechnology dr tESFAYE - Video - April 25th, 2014 [April 25th, 2014]
- Algenist Skincare: Biotechnology from San Francisco - Video - April 27th, 2014 [April 27th, 2014]
- nitj biotechnology farewell batch2010-14 - Video - April 28th, 2014 [April 28th, 2014]
- Life Sciences & Biotechnology - Video - April 28th, 2014 [April 28th, 2014]
- Bolder Biotechnology Current Therapeutic Market Developmental Pipeline - Video - April 28th, 2014 [April 28th, 2014]
- Academic and Research Institutions to Play Key Role in 2014 BIO International Convention - April 29th, 2014 [April 29th, 2014]
- 19 Biotechnology - Video - April 29th, 2014 [April 29th, 2014]
- BIOTECHNOLOGY - Video - April 29th, 2014 [April 29th, 2014]
- Program Spotlight: Biotechnology - Video - April 30th, 2014 [April 30th, 2014]
- Biotechnology at Gaston College - Video - April 30th, 2014 [April 30th, 2014]
- Biotechnology - Gene Cloning - Video - April 30th, 2014 [April 30th, 2014]
- Amyris helps launch Brazilian Industrial Biotechnology Association (ABBI) - Video - May 2nd, 2014 [May 2nd, 2014]
- Julius Mugwagwa - Agro-biotechnology and Food Security - Video - May 2nd, 2014 [May 2nd, 2014]
- VIRUN's CEO, Philip Bromley, lecture - Cal Poly Pomona; Biotechnology - Video - May 2nd, 2014 [May 2nd, 2014]
- Biotechnology - gel electrophoresis - Video - May 2nd, 2014 [May 2nd, 2014]
- Plant Biotechnology Information Fair at Penn State 4/18/14 - Video - May 2nd, 2014 [May 2nd, 2014]
- Biotechnology ADHK - Video - May 2nd, 2014 [May 2nd, 2014]
- General Biology 2 - 38 Angiosperm Reproduction and Biotechnology - Flashcards - Video - May 2nd, 2014 [May 2nd, 2014]
- Impact of Biotechnology on Current Life - Video - May 3rd, 2014 [May 3rd, 2014]
- DGAP-Adhoc: Cytos Biotechnology Ltd to wind down Key Operational Activities - May 5th, 2014 [May 5th, 2014]
- Process - Genetic Engineering and Biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- SAT105 Unit 3 Part 2 Biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- highlights of industrial biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- polymer & environmental biotechnology @ acib - Video - May 8th, 2014 [May 8th, 2014]
- SAT105 Unit 3 Part 1 Biotechnology - Video - May 8th, 2014 [May 8th, 2014]
- Talk of the Trade: Biotechnology & Health Sciences - Video - May 9th, 2014 [May 9th, 2014]
- Congratulations to the 2014 Biotechnology Graduates of Athens Technical College! - Video - May 9th, 2014 [May 9th, 2014]
- Plandai Biotechnology (PLPL) - Getting the Most Out of Nature - Video - May 10th, 2014 [May 10th, 2014]
- Stages Of Beans Growth- HU biotechnology - Video - May 11th, 2014 [May 11th, 2014]
- Revisiting the biotechnology stocks - Video - May 11th, 2014 [May 11th, 2014]
- Molecular Biotechnology - Master's Programme - Video - May 11th, 2014 [May 11th, 2014]
- Kevin Ahern's BB 350 (Biotechnology) 2014 - #22 - Video - May 12th, 2014 [May 12th, 2014]
- 5/5, Session 1 - Small biotechnology/Venture capital - Video - May 12th, 2014 [May 12th, 2014]
- Executive Interview - International Biotechnology Trust - Video - May 12th, 2014 [May 12th, 2014]
- Biotechnology Salaries | Salary.com - May 14th, 2014 [May 14th, 2014]
- Biotechnology | University of Wrocaw - Video - May 14th, 2014 [May 14th, 2014]
- JVS Bridges to College - Biotechnology Pathway Program - Video - May 16th, 2014 [May 16th, 2014]
- Biotechnology Paperslide Review by Khalizarek+Brian - Video - May 16th, 2014 [May 16th, 2014]
- Perceptions on the Future of Biotechnology by Robert Paarlberg (USA) - Video - May 16th, 2014 [May 16th, 2014]
- Plant Biotechnology - Video - May 16th, 2014 [May 16th, 2014]
- Playing with Biotechnology at the Age of 20: Kinshuk Mitra at TEDxOhioStateUniversity - Video - May 16th, 2014 [May 16th, 2014]
- biotechnology movie - Video - May 19th, 2014 [May 19th, 2014]
- New report details biotechnology's use in crops - May 20th, 2014 [May 20th, 2014]
- Biotechnology Stock Wins - Video - May 20th, 2014 [May 20th, 2014]
- Plant product of biotechnology - Video - May 21st, 2014 [May 21st, 2014]
- How Biotechnology Cure Diabetes - Video - May 22nd, 2014 [May 22nd, 2014]
- Exploring Laser-Material Interaction for Engineering, Biotechnology, and Medicine #DigInfo - Video - May 22nd, 2014 [May 22nd, 2014]
- Computers, Biotechnology, and Mass Communication - Video - May 22nd, 2014 [May 22nd, 2014]